Neuphoria Therapeutics, Inc. (NEUP)
3.89
+0.09
(+2.37%)
USD |
NASDAQ |
Dec 18, 16:00
3.85
-0.04
(-1.03%)
Pre-Market: 08:32
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 7.313M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 1.38K% |
| Valuation | |
| PE Ratio | 4.306 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 14.87 |
| Price to Book Value | 0.5846 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0094 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. |
| URL | http://www.neuphoriatx.com |
| Investor Relations URL | https://ir.neuphoriatx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. |
| URL | http://www.neuphoriatx.com |
| Investor Relations URL | https://ir.neuphoriatx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |